NeuroBo Pharmaceuticals announced that the U.S. FDA has cleared its Investigational New Drug application for DA-1726, a novel, dual oxyntomodulin analog agonist that functions as a glucagon-like peptide-1 receptor and glucagon receptor. The company plans to initiate a Phase 1 clinical trial, for the treatment of obesity, in the first half of this year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NRBO:
- NeuroBo announces pre-clinical safety data of DA-1241 with sitagliptin
- NeuroBo Pharmaceuticals regains Nasdaq compliance
- NeuroBo submits IND application to FDA for Phase 1 trial of DA-1726
- NeuroBo Pharmaceuticals trading halted, news pending
- NeuroBo Pharmaceuticals announces 1-for-8 reverse stock split
